Friday, January 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

CRADA Opportunity: Developing Protein Nanoparticles for the Display of Viral Epitopes

by Global Biodefense Staff
March 13, 2019
Nanoscale CBRN Defense

Credit: Shutterstock

The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health seeks to partner with one or more biomedical companies in developing protein nanoparticles for the display of viral epitopes for vaccine use.

The Cooperative Research and Development Agreement (CRADA) would require the following capabilities:

  • Produce scaled- up purified recombinant protein nanoparticles
  • Measure antibody levels/titers elicited by nanoparticles
  • Measure neutralization capacity of antibodies to a panel of influenza viruses
  • Produce hydridomas or cDNA clones of neutralizing antibody genes elicited by nanoparticles
  • Produce quantities of antibodies sufficient for challenge and protection studies in animal models

CRADA partners will be expected to carry out additional immunogenicity studies in small animal mouse models with NIAID’s protein nanoparticles and if the data are promising, clinical studies may be discussed. It is especially desired that a prospective CRADA partner has expertise in performing and analyzing vaccination of animals with influenza immunogens/viruses and has the ability to perform challenge and protection studies in animals with a candidate influenza vaccine to expand on the initial studies performed by NIAID.

Additional details are available via FedBizOpps Solicitation Number: NIAID-TTIPO-2016-032.

Tags: InfluenzaNIAIDRFIVaccines

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC